A Phase 4 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Completed at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 162nd largest by enrollment, is one of 31 that started in 2022, is one of 5 in phase 4, and was the 199th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 26 · Phase 4 5
First in 2010; this study’s year is marked. 31 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 57 across the 202 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 202 have an industry lead sponsor. The 10 most frequent:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh is the lead sponsor of 128 studies on the registry; 22 are open to participants now.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who could not receive intensive induction chemotherapy. Twenty-four patients were enrolled at the Department of Haematology, Dhaka Medical College Hospital, Dhaka, Bangladesh. In addition to older and comorbid patients, the cohort included younger patients for whom intensive chemotherapy was financially inaccessible - a population under-represented in existing trial and registry data. The primary endpoint was the composite remission rate (complete remission plus complete remission with incomplete haematologic recovery) assessed by bone marrow examination on Day 28. Secondary endpoints included change in complete blood count parameters, treatment-emergent adverse events, and 28-day mortality.
Background and Rationale
Acute myeloid leukemia (AML) predominantly affects older adults, who often cannot tolerate intensive induction chemotherapy due to comorbidity or poor performance status. In low- and middle-income countries like Bangladesh, a secondary population-younger, medically fit patients-is also unable to receive intensive therapy due to prohibitive costs. While hypomethylating agents (HMAs) combined with venetoclax represent a standard lower-intensity approach, real-world data on this regimen are lacking in Bangladesh and sparse for financially constrained younger cohorts. This study evaluates the short-term outcomes of a single cycle of venetoclax plus an HMA in both groups at a public tertiary care hospital.
Intervention Details \& Dosing Nuances
Participants receive one 28-day cycle consisting of either IV azacitidine (75 mg/m² daily on Days 1-7) or IV decitabine (20 mg/m² daily on Days 1-5), based on physician discretion. Oral venetoclax is administered at 100 mg on Day 1, 200 mg on Day 2, and maintained at 100 mg daily from Day 3 to Day 28. The venetoclax dose is intentionally capped at 100 mg daily (instead of standard higher dosing) because all participants receive concomitant oral voriconazole (200 mg twice daily, Days 3-28) for antifungal prophylaxis, a strong CYP3A4 inhibitor requiring mandatory venetoclax dose reduction. Tumour lysis syndrome prophylaxis and standard supportive care (transfusions, antimicrobials) are provided per institutional protocols.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm. All participants received one 28-day cycle of venetoclax combined with either azacitidine or decitabine at investigator discretion, with antifungal prophylaxis.
Drug: Venetoclax · Drug: Azacitidine · Drug: Decitabine · Drug: Voriconazole
Oral venetoclax 100 mg on Day 1, 200 mg on Day 2, then 100 mg daily Days 3-28. Dose maintained at 100 mg from Day 3 because of concomitant strong CYP3A4 inhibition by voriconazole.
75 mg/m² intravenously, Days 1-7 of the 28-day cycle.
20 mg/m² intravenously, Days 1-5 of the 28-day cycle.
200 mg orally twice daily, Days 3-28, as antifungal prophylaxis.
Composite remission rate (CR + CRi) after one cycle
Proportion of participants achieving complete remission (bone marrow blasts \<5%, absence of circulating blasts and Auer rods, no extramedullary disease, ANC ≥1000/µL, platelets ≥100,000/µL) or CR with incomplete haematologic recovery (all CR criteria except residual neutropenia or thrombocytopenia), assessed on Day 28 bone marrow examination.
Time frame: Day 28 (end of cycle 1)
Change in total WBC count from baseline
Time frame: Baseline and Day 28
Change in absolute/differential neutrophil count from baseline
Time frame: Baseline and Day 28
Change in haemoglobin concentration from baseline
Time frame: Baseline and Day 28
Change in platelet count from baseline
Time frame: Baseline and Day 28
Change in peripheral blood blast percentage from baseline
Time frame: Baseline and Day 28
Change in bone marrow blast percentage from baseline
Time frame: Baseline and Day 28
Number of participants with treatment-emergent adverse events
Time frame: Day 1 to Day 28
All-cause mortality
Time frame: Day 1 to Day 28
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Mar 2023, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh →